Drug Search Results
More Filters [+]

Hydroquinone

Alternative Names: hydroquinone
Latest Update: 2024-09-18
Latest Update Note: News Article

Product Description

Hydroquinone is a topical skin-bleaching agent used in the cosmetic treatment of hyperpigmented skin conditions. Hydroquinone produces reversible lightening of the skin by interfering with melanin production by the melanocytes. Specifically, inhibition of the enzymatic conversion of tyrosine to DOPA (dihydroxyphenylalanine) results in the desired chemical reduction of pigment. Ultimately, this causes a decrease in the number of melanocytes and decreased transfer of melanin leading to lighter skin. (Sourced from: https://www.aocd.org/page/Hydroquinone)

Mechanisms of Action: Melanin Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Brazil | Canada | Chile | Colombia | Dominican Republic | Ecuador | Egypt | Hong Kong | India | Indonesia | Israel | Jordan | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | Spain | Sri Lanka | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Cynosure
Company Location: WESTFORD MA 01886
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Hydroquinone

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20200866

P3

Not yet recruiting

Other

None

Recent News Events